Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "BioNTech"

48 News Found

Study shows Pfizer vaccine moderately effective against Omicron for children 5-15
News | March 12, 2022

Study shows Pfizer vaccine moderately effective against Omicron for children 5-15

The study looked at 1,364 children in Arizona, Florida, Texas, and Utah who submitted weekly nasal swabs and surveys from July 2021 through February 2022, regardless of whether they had symptoms


Solvay awards €300k science prize to Prof Katalin Kariko for research in mRNA technology
News | January 18, 2022

Solvay awards €300k science prize to Prof Katalin Kariko for research in mRNA technology

Prof Karikó's research was most notably used by Pfizer/BioNTech and Moderna to build COVID-19 mRNA vaccines


DaVita research indicates effectiveness of mRNA vaccine in dialysis patients
News | November 30, 2021

DaVita research indicates effectiveness of mRNA vaccine in dialysis patients

Researchers observed that the Pfizer/BioNTech and Moderna vaccines were 78% and 73% effective in preventing Covid-19 infections, respectively


U.S. FDA allows Pfizer and Moderna booster doses for all
News | November 20, 2021

U.S. FDA allows Pfizer and Moderna booster doses for all

This is a shot in the arm for the vaccine manufacturers


U.S. FDA gives green light to Moderna and J&J booster doses
Drug Approval | October 21, 2021

U.S. FDA gives green light to Moderna and J&J booster doses

The authority also allowed mix and match of booster doses once the primary vaccine has been administered.


Covid-19 vaccine clinical trial for people with autoimmune disease
Drug Approval | September 03, 2021

Covid-19 vaccine clinical trial for people with autoimmune disease

Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study


Brazil’s Eurofarma to manufacture Comirnaty for Latin America
Biotech | August 27, 2021

Brazil’s Eurofarma to manufacture Comirnaty for Latin America

The manufacture of finished doses will commence in 2022 and at full operational capacity, the annual production is expected to exceed 100 million doses annually


Merck FY20 sales up 8.6% euro 17.5 bn
News | March 04, 2021

Merck FY20 sales up 8.6% euro 17.5 bn

Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.